IngredientsThe accepted scientific name is Fouquieria splendens Engelm., commonly known as ocotillo, and also called Candlewood, Coach Whip, and Devil's Walking Stick (Spanish: Ocotillo, Albarda, Barda, Ocotillo del Corral). It belongs to the family Fouquieriaceae. Recognized subspecies include F. splendens subsp. splendens and F. splendens subsp. campanulata (Nash) Henrickson.
Ocotillo is known by several common names, including buggywhip, coachwhip, candlewood, slimwood, desert coral, Jacob's staff, Jacob cactus, ocotillo tree, and vine cactus. The name "Ocotillo" originates from the Nahuatl language, spoken by the Aztecs; the root word ocotl means "ocote" or "torch" in English, referring to the plant's long, slender, candle-like stems.
Fouquieria splendens is commonly the most popular desert plant native to the southwestern United States and northern Mexico. Despite its common name, ocotillo is not a true cactus but belongs to the succulent family Fouquieriaceae. Ocotillos look desiccated on the outside but are semi-succulent; the plant is more closely related to the tea plant and blueberries than to cactus.
Ocotillo is a deciduous shrub characterized by its tall, slender, and upright stems which can reach heights of up to 20 feet (6 meters) or more. The stems are typically green and, when healthy, can photosynthesize, allowing the plant to thrive during dry spells. The branches are often spiny, providing a defense mechanism against herbivores. Leaves on the ocotillo plant are small and typically appear in clusters. Small oval to obovate leaves grow bundled around the stem in an alternate and helical pattern in response to precipitation. The leaves take 2–3 weeks to mature before they abscise, leaving the remains of the petiole to harden into a blunt ½-inch to 1-inch spine.
The loss of leaves during dry periods and the waxy coating on the stem both contribute to the plant's ability to conserve water. Flower buds produce nectar glands that attract hummingbird pollinators, and bright orange-red tubular flowers are borne on panicles at the tip of the stems before leaves appear in the spring.
Fouquieria splendens is indigenous to the Mojave, Sonoran, Chihuahuan, and Colorado Deserts in the Southwestern United States (southern California, southern Nevada, Arizona, New Mexico, Texas), and northern Mexico (as far south as Hidalgo and Guerrero).
In contemporary herbal commerce, ocotillo is primarily available in the following forms, derived predominantly from the stem bark:
Ocotillo faces threats from climate change and development, particularly in California's Anza-Borrego Desert State Park. In both Arizona and California, it is a protected plant, and digging it up is illegal. Commercially sold preparations therefore often specify sustainably wildharvested or cultivated sources.
Indigenous peoples of the Southwest developed a long, mutually beneficial relationship with ocotillo across the Sonoran, Mojave, and Chihuahuan Deserts. It offered food and drink, medicine, materials for shelter, and was used in ceremonies. Peoples including the Cahuilla, Pima, Hualapai, Tohono O'odham, Apache, and Seri worked with ocotillo as it was available.
Medicinal uses by specific groups:
Food uses:
Construction and material uses:
In traditional medicine, the stems of F. splendens are used by ethnic groups to treat circulatory problems, cough, varicose veins, urinary tract infections, pain, and colds. Flowers are used to make infusions to treat cough and colds. Leaves are used as a diuretic, against stomach pain, cough, dysentery, and respiratory diseases.
Ocotillo has been used in Mexican traditional medicine for the treatment of blood circulation problems, swelling, and prostatic hyperplasia, among others.
In modern Western herbalism, particularly within the Southwestern tradition, ocotillo bark tincture is employed principally as a lymphagogue (a substance purported to promote lymph flow) and pelvic decongestant. Ocotillo bark was often prepared as a tincture or decoction to support lymphatic flow, reduce swelling, and alleviate congestion, particularly in the lower body. It was a valued aid for addressing pelvic stagnation, urinary discomfort, and respiratory congestion. These contemporary applications, while widespread in herbal practice, remain without published clinical trial support.
The extracts of leaves and stem of F. splendens have shown the presence of flavonoids — including quercetin-3-O-glycoside, myricetin, apigenin, rutin, kaempferol-3,4-dimethyl ether, luteolin, isoquercitrin, kaempferol-3-O-glucoside, catechol, epigallocatechin gallate, and scopoline — and phenolic acids including ellagic acid, gallic acid, chlorogenic acid, and cinnamic acid. In addition, anthocyanins (delphinidin-3-glycoside, cyanidin-3-glycoside, and pelargonidin-3-glycoside) have been identified.
The ethyl acetate fraction of a methanolic leaf extract exhibited the highest amount of phenolic compounds (479.9 mg GAE/g), with the predominant compounds being gallic acid (25.949 mg/g) and ellagic acid (17.439 mg/g).
In the ethanolic foliar extract (EFS), eleven phenolic compounds were identified, including ellagic acid, morin, apigenin, and luteolin 7-O-glucoside.
Flowers and barks of F. splendens show the presence of terpenes including ocotillol, fouquierol, and isoforquierol.
Ocotillol, isolated from Fouquieria splendens Engelm., bears a characteristic tetrahydrofuran ring at C-20. The presence of ocotillol, a triterpene, in the bark of F. splendens was first reported by Basey & Halls (1965).
The presence of phenols, flavones, and flavonols on the surfaces of leaves and stems, as well as ocotillol in the cortex, indicates that this species may be a promising candidate for the treatment of chronic diseases such as diabetes.
In a 2022 analysis of volatile compounds from ocotillo stems using multiple extraction methods and solvents, the major components identified were bis(2-ethylhexyl) phthalate, bis(2-ethylhexyl) ester, butyl acetate, palmitic acid, and myristic acid.
The presence of iridoid glucosides in species of the family Fouquieriaceae has been reported. The compounds adoxoside and loganin, as well as a few other related iridoids, have been identified.
Soil parameters are the factors determining particular quantitative phenolic profiles. The analyzed subspecies and populations show similar chemical patterns; however, quantitative variations, determined by soil texture, electrical conductivity, organic matter, organic carbon, and contents of potassium, calcium, and sodium, allow differentiation between them.
Research has revealed that the foliar tissues of F. splendens are rich in phenolic compounds such as ellagic acid and flavonols, including derivatives of myricetin, rutin, and quercetin-3-O-glycoside. These compounds exhibit antihyperglycemic, antioxidant, anti-inflammatory, hepatoprotective, and nephroprotective properties. The broad phenolic content of the plant — measured via DPPH, TEAC, ORAC, and FRAP radical-scavenging assays — is considered the principal biochemical basis for its observed antioxidant activity. All such mechanistic data are currently derived exclusively from in vitro laboratory models.
Antihyperglycemic effects have been attributed to the action of compounds including apigenin, ellagic acid, hyperoside, luteolin-7-O-glucoside, quercitrin, and kaempferol. Several mechanisms of action have been proposed, some already well characterized, such as inhibition of key metabolic enzymes protein tyrosine phosphatase 1B (PTP-1B), dipeptidyl peptidase-IV (DPP-IV), α-amylase, or aldose reductase enzymes, as well as stimulating insulin secretion and the enhancement of insulin sensitivity. These proposed mechanisms are based on the known pharmacology of the constituent compounds and require direct confirmation in studies using F. splendens extracts specifically.
Ocotillol-type terpenoid antiseptic molecules from the ocotillo plant have been identified, and their ability to improve the susceptibility of some antibiotics has been determined, showing strong effects against bacteria such as S. aureus, B. subtilis, and even P. aeruginosa, as these molecules may exert their antibacterial effect by damaging bacterial cell membranes.
It is essential to note that, as of 2025, there are no published randomized controlled trials or other human clinical studies evaluating ocotillo for any health indication. The totality of formal scientific evidence resides at the preclinical level (animal and in vitro studies). The following sections describe that evidence with explicit notation of its type and limitations.
Study type: In vitro cell-line study. Published: 2021 (ScienceDirect / Elsevier).
Scientific evidence about the biological activities of F. splendens is limited. The objective of a key 2021 study was to determine phenolic composition, antioxidant, and antiproliferative effects of F. splendens. A methanolic extract from F. splendens leaves was obtained and fractionated by liquid-liquid partition to yield hexane, ethyl acetate, and residual fractions. Phenolic compounds were determined by the Folin-Ciocalteu method, and the phenolic profile was assessed by UPLC-DAD. Antioxidant activity was determined by DPPH, TEAC, ORAC, and FRAP assays, and antiproliferative activity was assessed by MTT assay against C33-A and HeLa cell lines.
The ethyl acetate fraction, richest in gallic acid (25.949 mg/g) and ellagic acid (17.439 mg/g), demonstrated the highest phenolic content and corresponding antioxidant activity. Antiproliferative effects were observed against the tested cervical cancer cell lines (C33-A and HeLa) in the MTT in vitro assay.
Limitations and evidence strength: These findings are entirely in vitro and cannot be extrapolated to human efficacy. No animal study or human clinical trial has tested these antiproliferative effects. Evidence is preliminary and exploratory.
Study type: Preclinical animal study (rat model). Published: November 2025 (MDPI Future Pharmacology).
This 2025 study investigated the phytochemical composition, oral acute toxicity, mutagenicity, and antihyperglycemic activity of the foliar ethanolic extract of F. splendens (EFS), as antihyperglycemic properties and safety profiles had remained poorly studied. Acute toxicity and mutagenicity were evaluated following OECD guidelines. Antihyperglycemic activity was assessed in streptozotocin-induced diabetic rats treated with EFS at 200 mg/kg, alone or in combination with metformin, for 30 days.
Eleven phenolic compounds were identified in the EFS, including ellagic acid, morin, apigenin, and luteolin 7-O-glucoside. EFS was non-mutagenic and had an LD50 of greater than 2000 mg/kg. This treatment significantly reduced blood glucose levels and enhanced the effect of metformin in diabetic rats. Histopathological analysis showed preserved morphology in the pancreatic, hepatic, and renal tissues of the treated animals. EFS exhibited significant antihyperglycemic activity and a favorable safety profile, supporting its potential as a complementary phytotherapeutic agent for diabetes management.
This study provides, for the first time, phytochemical characterization, acute toxicity assessment, genotoxicity, and mutagenic assays alongside in vivo information on the antihyperglycemic effects of EFS. There was previously no evidence for the antihyperglycemic potential of F. splendens.
Limitations and evidence strength: This is a single preclinical animal study using a streptozotocin-induced diabetic rat model, which does not reliably predict human outcomes. No human clinical trials exist. The evidence is preliminary and requires replication. The dosage of 200 mg/kg in rats does not translate directly to human dosing.
Study type: In vitro antimicrobial/phytochemical analysis.
Ocotillol-type terpenoid molecules from ocotillo have been identified and their ability to improve the susceptibility of some antibiotics has been determined, showing strong effects against bacteria such as S. aureus, B. subtilis, and P. aeruginosa, as these molecules may exert their antibacterial effect by damaging bacterial cell membranes.
Research on synthetic derivatives of the ocotillol-type scaffold is ongoing in the broader chemical literature. A novel series of ocotillol-type lactone derivatives were designed and synthesized to study their antibacterial activity and structure-activity relationships. Compounds 4j and 4m were found to be the most active, with minimum inhibitory concentrations of 1–4 µg/mL against Gram-positive bacteria, and showed low cytotoxicity against MCF-7, HEK-293, and HK-2 cells at their MICs.
Methanol extracts of the ocotillo root also show phytotoxic activity against Lactuca sativa and Lolium perenne, and herbicide activity against the green peach aphid Myzus persicae.
Limitations and evidence strength: All findings are in vitro or relate to derivative compounds, not the crude plant material or standardized extracts tested in humans. Translational relevance is unestablished.
Compounds found in F. splendens — including ellagic acid and quercetin derivatives — exhibit anti-inflammatory properties based on known pharmacology of these compound classes. No dedicated in vivo or in vitro anti-inflammatory study specifically using F. splendens extracts has been published in the peer-reviewed literature retrievable as of 2025. Claims of anti-inflammatory activity are extrapolated from the known activities of the plant's constituent phenolic compounds.
Limitations and evidence strength: The anti-inflammatory activity of ocotillo as a whole extract remains unvalidated by direct experimental studies. Evidence is indirect and constitutive only.
Study type: Preclinical toxicology (OECD-guideline rodent study). Published: 2025.
Acute toxicity and mutagenicity were evaluated following OECD guidelines. EFS was found to be non-mutagenic and demonstrated an LD50 of greater than 2,000 mg/kg — a threshold generally classified as "practically non-toxic" per standard toxicological ranking systems. Histopathological analysis showed preserved morphology in the pancreatic, hepatic, and renal tissues of the treated animals.
A separate 2022 study assessed the toxicity of stem extracts using the Artemia salina brine shrimp bioassay. Probit analysis revealed that extracts isolated by non-polar solvents of F. splendens are not suitable for use in phytotherapy because their high content of DEHA and DEHP (phthalate plasticizers detected as laboratory contaminants or genuine plant metabolites) and LC50 values under 100 ppm make them extremely toxic in that assay. However, in polar extracts, there are molecules such as 2-butoxyethanol, pentadecanol, and undecanal that allow justification of the use of ocotillo in traditional medicine, because these molecules have proven insecticide capacity and antimicrobial potential.
Limitations: These are preliminary safety assessments in animal models and cell-free assay systems. Long-term subchronic or chronic toxicity in humans has not been evaluated. The relevance of LC50 values in brine shrimp to human toxicity is indirect.
Based on the combination of ethnobotanical records and available preclinical science, ocotillo has been associated with the following body systems. Evidence quality for each is noted.
No standardized dosages for ocotillo have been established by any regulatory or pharmacopoeial authority. The following are dosages reported in traditional herbal practice references and commercial preparations; they do not represent clinical trial dosages or regulatory-approved amounts, except where noted.
In the 2025 OECD-guideline study, EFS was found to be non-mutagenic and demonstrated an LD50 greater than 2,000 mg/kg in the rodent acute oral toxicity model. Histopathological analysis showed preserved morphology in the pancreatic, hepatic, and renal tissues of treated animals. These findings suggest a favorable acute safety profile for polar (e.g., ethanolic) extracts at preclinical levels, but chronic toxicity data in humans is absent.
Probit analysis revealed that extracts isolated by non-polar solvents of F. splendens are not suitable for use in phytotherapy, because their high content of DEHA and DEHP and LC50 values under 100 ppm make them extremely toxic in the Artemia salina bioassay model. This finding underscores that the solvent system used in preparation of ocotillo extracts meaningfully affects safety, with polar extracts (water, ethanol, methanol) considered more suitable than non-polar preparations (hexane-based).
According to one herbal materia medica reference, "Ocotillo should be avoided when: organic disorders, thrombosis, cholinergic dominance, pregnancy, or overt lymph or immune pathologies are present." These contraindications are based on empirical clinical herbalist observation rather than formal clinical data.
There is no known toxicity in reasonable amounts as a food or medicine; however, due to its blood-moving nature, this herb is considered by traditional practitioners to be contraindicated during pregnancy.
Modern scientific validation for ocotillo's medicinal use remains limited, with few published clinical studies directly evaluating its efficacy or safety. No drug interaction studies, pharmacokinetic studies in humans, or long-term safety trials have been published. Given the presence of terpene compounds such as ocotillol with documented cell-membrane-disrupting properties at laboratory concentrations, and the detection of phthalate-type compounds in non-polar stem extracts, both extract preparation method and dosage require careful attention.
Ocotillo faces threats from climate change (drought and extreme heat) and development, particularly in California's Anza-Borrego Desert State Park. In both Arizona and California, it is a protected plant, and digging it up is illegal. This creates important practical and ethical considerations for the sourcing of commercial preparations, with sustainable wildcrafting and cultivated sources being the appropriate supply pathways.
Scientific evidence about the biological activities of Fouquieria splendens is limited. The plant has a well-documented ethnobotanical history across multiple indigenous cultures of the American Southwest and Mexico, and modern phytochemical analyses have confirmed a rich array of phenolic compounds, terpenes, and iridoids with recognized pharmacological relevance in other contexts. However, formal clinical evidence in humans for any indication is entirely absent. The most rigorous published study to date (2025) is a single preclinical animal study demonstrating antihyperglycemic activity and acceptable acute toxicity in rats. All other biological activities — antimicrobial, anti-inflammatory, antiproliferative, circulatory, and lymphatic — are supported only by in vitro data, traditional use records, or the pharmacological properties of isolated constituent compounds. Substantial additional research, including well-designed human trials, is required before any evidence-based clinical conclusions can be drawn.
Health conditions that Ocotillo may help support.
Body systems that Ocotillo may help support.
Go back